Dear colleagues,

I am excited to be a part of the Oregon Health & Science University community. Since joining OHSU as the Vice President for Technology Transfer and Business Development last year, I have witnessed a vibrant entrepreneurial ecosystem emerging in the Portland area. While there are undoubtedly challenges that remain to be overcome, Technology Transfer and Business Development is committed to assisting our researchers and entrepreneurs in their efforts, and will be announcing new initiatives in the months to come. With the tremendous caliber of research and people at OHSU, I am confident that OHSU's continuing collaboration and partnership efforts will advance the translation of our clinical and research expertise for the benefit of patients, the university, and society.

On Thursday, March 31, we will host the fourth annual OHSU Startup Symposium to showcase OHSU startup companies and innovations. This year's conference, Connecting the Pacific Northwest Life Science Ecosystem, invites the region's most prominent and relevant life science investors to meet, greet, and discuss the most pressing issues of life science investment today. The keynote address will be given by John L. Flannery, President and CEO of GE Healthcare. I invite you to this event to learn more about OHSU startup companies and inventions, and to participate in timely and interesting discussions with top industry executives. Please join me on March 31 — I look forward to meeting you.

Brendan Rauw, M.B.A., C.L.P.
Vice President, Technology Transfer and Business Development
EVENTS

Join us for the 2016 OHSU Startup Symposium on March 31: "Connecting the Pacific Northwest Life Science Ecosystem"

Register today

Visit Event Webpage

FEATURES

OHSU startup receives $11.45 million to help treat neurologic disorders

NeuroVia, Inc., an OHSU startup company, recently closed Series A equity financing, raising $11.45 million to support the company's mission and commitment to developing therapeutics for the treatment of neurological disorders. Thomas Scanlan, Ph.D., professor of
physiology and pharmacology and director of the OHSU program in chemical biology, is the founder of NeuroVia. Novartis Venture Fund, Sanofi–Genzyme Bioventures, and BioMed Realty Ventures participated in the Series A financing.

OHSU, GE Healthcare team up to explore new frontiers in health care innovation

Oregon Health & Science University and GE Healthcare have signed a memorandum of understanding to develop collaborative research programs in cardiovascular medicine, imaging and big data research. The research programs are aimed at bringing together OHSU's clinical expertise with GE Healthcare's technology prowess to answer fundamental questions in biology and medicine.

TECHNOLOGIES FOR LICENSING

# 1917 - Ultrasound needle guide

# 1982 - Aqueous cell differentiation in anterior uveitis using OCT

# 0681 - CORPORA from CSLU
# 2142 - Super-resolution image analysis for 2D/3D reconstruction

## More Technologies

### ISSUED PATENTS

# 1238 - Compounds having antiparasitic or anti-infectious activity

# 1353 - Rapid confocal microscopy to support surgical procedures

# 1851 - Novel pyrroloquinazolines as anti-cancer agents

## OHSU TECHNOLOGIES IN THE NEWS

OHSU Knight Cardiovascular creates company to build first total artificial heart

OncoResponse and Oregon Health & Science University collaborate to identify novel immuno-oncology targets

Apple announces new ResearchKit studies for Autism, Epilepsy, and Melanoma

Visit the Technology Transfer and Business Development website for more information.
Privacy Policy
Email or mailing addresses are never sold or shared by OHSU.

Unsubscribe
Unsubscribe from all OHSU email